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Abstract
Objectives—To determine if selected socio-demographic and HBV-specific clinical factors are 
associated with health-related quality of life (HRQoL) among pediatric patients chronically 
infected with hepatitis B virus (HBV).
Methods—Children with chronic HBV enrolled in the Hepatitis B Research Network completed 
the Child Health Questionnaire (CHQ) at study entry. Caregivers of children 5–<10 years 
completed the parent-reported PF50; youth 10–< 18 years completed the child-reported CF87. We 
examined univariable associations of CHQ scores with selected independent variables: sex, 
adoption status, maternal education, alanine aminotransferase (ALT, U/L), aspartate 
aminotransferase-to-platelet ratio index (APRI), and HBV-specific symptom count.
Results—244 participants (83 young children 5–<10y, 161 youth 10–<18y) were included, all 
HBV treatment naïve. Among young children, increased ALT level was negatively associated with 
PF50 psychosocial summary T-Score (r=−0.28, p=0.01). No other subscale comparisons for young 
children were statistically significant. Among youth, adoption was associated with better physical 
functioning and general health (p<0.01). Higher maternal education was associated with better 
role/functioning-physical and -emotional scores (p<0.05). Maternal education and adoption status 
were linked, with adoption associated with higher maternal education. Increased symptom count in 
youth was associated with worse HRQoL in subscales measuring bodily pain, behavior, mental 
health, and self-esteem (p<0.01).
Conclusions—Although overall HRQoL is preserved in children with chronic HBV, some 
socio-demographic and HBV-related clinical factors were associated with impaired HRQoL in our 
pediatric patients at baseline. Measurement of HRQoL can focus resources on education and 
psychosocial support in children and families most in need.
Keywords
Child Health Questionnaire; adoption; refugee; hepatitis B; quality of life; chronic medical 
condition; children
Introduction
Chronic hepatitis B (HBV) infection is associated with significant morbidity and mortality, 
with 25% of infected individuals developing cirrhosis and/or hepatocellular carcinoma (1, 
2). Universal vaccination and prenatal screening in the US and Canada have decreased the 
incidence of chronic HBV in children born in these countries. However, new cases of 
childhood hepatitis B are seen in North America in children of immigrants and children 
adopted internationally (3–5). On average, 53,800 chronic HBV cases were imported to the 
US annually during 2004 – 2008 (4).
Adults with chronic HBV experience decreased health-related quality of life (HRQOL) (6) 
but there is little information about HRQOL in children with HBV. HRQoL is a complex and 
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inherently subjective measure that is an important outcome of disease management. 
Impaired HRQoL has been associated with poor medication adherence, depression, anxiety 
and worse health outcomes (7). Importantly, patients and their families may make treatment 
decisions for chronic disease management based upon how treatments affect HRQoL and 
life functioning (8). The measurement of HRQoL in children with chronic HBV has the 
potential to allow early interventions that may reduce adult depression and increase 
adherence to therapies for HBV.
The Hepatitis B Research Network (HBRN) (9) provides a unique opportunity to study a 
large, well-characterized cohort of children with chronic HBV infection in the US and 
Canada (5). Using this cohort, we assessed HRQoL in children and youth with chronic HBV 
using an age-appropriate instrument, the Child Health Questionnaire (CHQ) (10). In this 
exploratory study, our aim was to describe the HRQoL of children with chronic HBV and 
their families, and to examine selected socio-demographic and disease-related factors 
associated with HRQoL in our cohort. This will contribute to the overarching goal of the 
Pediatric HBRN, to improve the lives of children with chronic HBV.
Methods
Seven pediatric hepatology centers in the US and Canada participated in the HBRN 
Pediatric Cohort study (5, 9). Subject inclusion criteria included age 6 months to <18 years 
and hepatitis B surface antigen (HBsAg)-positive. Exclusion criteria included history of 
hepatic decompensation, hepatocellular carcinoma, solid organ or bone marrow transplant, 
co-infection with human immunodeficiency virus, current HBV anti-viral therapy, or social 
or medical factors that would make follow-up difficult.
The HRQoL sub-study included pediatric HBRN participants ≥5 to <18 years of age who 
were HBV treatment naive. English literacy was required for caregivers of children <10 
years of age and for children ≥10 years of age because translations were not available for 
several of the more common languages in the HBRN cohort. Participants for this analysis 
were enrolled between December 2010 and September 2015.
All sites had institutional review board approval. Written informed consent was obtained 
from parents or legal guardians; assent was obtained from children according to the 
requirements of the local institutional review board.
Measures
Socioeconomic and demographic characteristics—Demographic variables 
collected at entry into the study included age, sex, race, adoption status and measures of 
family socioeconomic status (e.g. maternal education).
Disease characteristics—Serum alanine aminotransferase (ALT, U/L) was recorded 
within 6 months of the baseline study visit. HBV DNA (IU/mL) and hepatitis e antigen 
(HBeAg) status were tested by a central laboratory. When central laboratory results were 
unavailable (e.g. due to inadequate sample), the most recent clinical results obtained within 
1 year (HBV DNA) or 2 years (HBeAg) of baseline were used. Other laboratory values, 
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including international normalized ratio (INR), albumin (g/dL), and direct bilirubin (mg/dL), 
were based on the latest values obtained within 1 year of baseline. On average, labs were 
taken <1.5 months prior to the baseline visit. Liver biopsies were not required as part of the 
cohort study; AST-to-platelet ratio index (APRI (11)) was calculated for each subject, with 
an AST of 40 U/L used as the upper limit of normal for this calculation to facilitate 
comparison with other studies using this index (12, 13). Symptom counts (0, 1, 2, 3+) were 
based on the following HBV-specific symptoms during the last month: fatigue, pain over 
liver, nausea, poor appetite, weight loss, itching, irritability, depression/sadness, jaundice, 
and dark urine.
Child Health Questionnaire (CHQ)—The CHQ was completed at the baseline visit. The 
CHQ is a validated instrument that measures generic HRQoL in the physical, psychological 
and social domains in children, including physical functioning (PF), bodily pain/discomfort 
(BP), general health (GH), general behavior (BE), mental health (MH), self-esteem (SE); 
role/social limitations as a result of physical (RP), emotional (RE), and behavioral (RB) 
problems; and the impact on parental time (PT), parental emotion (PE), and family activities 
(FA) (Table 1, Supplemental) (10). The CHQ-Parent Report Form (PF50) includes 11 
subscales, while the CHQ-Child Report Form (CF87) includes ten subscales. Each subscale 
is calculated by summing items to a total score of 0–100; higher scores reflect better 
HRQoL. Specifically for the PF50, two additional summary T-scores (physical and 
psychosocial) were derived by aggregating 10 individual scales (omitting the family 
activities subscale), and were standardized using a linear T-score transformation (mean 50, 
standard deviation 10) from the combined general U.S. sample (N=391) and six clinical 
samples (N=563) (14). The PF50 was administered to biological or adoptive parents or legal 
guardians, henceforth referred to as caregivers of young children 5–<10 years of age. 
Children who were at least 10 years of age (identified below as “youth”) completed the 
CF87 themselves.
Statistical Analysis
Summary statistics were used to describe demographic and disease-related characteristics. 
Mean with standard deviation (SD), or median with (25th percentile, 75th percentile) and 
(minimum, maximum) were reported for continuous variables. Frequencies and proportions 
were reported for categorical variables. Mean (SD) and 95% confidence intervals (CI) were 
calculated for each CHQ subscale and summary T-score. CHQ subscales were presented as 
radar plots to allow easy visualization of the range of mean scores across multiple subscales. 
The plot radius indicates the score (much like a y-axis); points farther out on the radar plot 
indicate higher scores (i.e. higher quality of life). Descriptive characteristics are presented 
for the overall sample and separately by age group. For descriptive comparison, we included 
summary scores from a group of adolescent liver transplant recipients (7.5 ± 5.7 years post-
transplant) (7) and a healthy pediatric population (15).
We examined univariable associations of CHQ scores with selected independent variables: 
sex, adoption status, maternal education, ALT (U/L), APRI, and HBV-specific symptom 
count. For categorical independent variables, CHQ summary T-scores were presented as 
mean (SD) by category; since subscale scores were skewed, median (25th percentile, 75th 
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percentile) were presented. Moreover, because >75% of participants obtained the maximum 
score (100) on several subscales, we also presented the frequency and percent of participants 
with subscale scores below 100. Kruskal-Wallis non-parametric tests were used to compare 
the distribution of CHQ scores across levels of categorical variables. Spearman correlation 
coefficients, with corresponding p-values, were used to assess the correlation of CHQ scores 
with continuous independent variables (ALT and APRI).
Sensitivity Analysis—Because flares are associated with increased liver enzymes, and 
may be associated with increased symptoms and decreased HRQoL, we repeated our 
analysis after excluding 1 younger and 5 older children with ALT flares, which was defined 
as an ALT more than 10 times the ULN using the following age- and sex-specific ULN cut-
points: 25 U/L for males and females 5–<13 year-olds, 25 U/L for males ≥13 years, and 22 
U/L for females ≥13 years (16, 17). Results for these sensitivity analyses were similar to 
those obtained with the full sample, and thus are not reported.
Statistical significance was determined as p<0.05. For subscale score comparisons, 
Bonferroni-Holm adjusted p-values were calculated to indicate statistical significance after 
accounting for multiple comparisons across the 11 and 10 subscales for the PF50 and CF87, 
respectively. SAS 9.3 (SAS Institute, Cary NC, USA) was used for statistical analyses.
Results
Demographic and clinical characteristics
As of September 2015, 395 children were enrolled in the HBRN Pediatric Cohort study; 330 
were at least 5 years of age. Of these, 280 were treatment naïve, and thus eligible to 
participate in the HRQoL study. 244 of these had CHQ data and were included in the 
analysis. The PF50 was available for 83 children 5–<10 years old, and the CF87 was 
available for 161 youth 10–<18 years old (see Table 1).
Demographic characteristics of 5–<10 year olds are found in Table 1.. Serum ALT levels 
ranged from 12–365 (median 39) U/L. The majority were HBeAg positive (91%), and 72% 
had HBV DNA levels ≥108 U/mL. INR ranged from 0.9–1.2, albumin 1.1–5.4 g/dL, and 
direct bilirubin 0.0–0.99 mg/dL. APRI median score was 0.37; four subjects (5.8%) had 
values above 1.0. Presumed mode of HBV transmission was vertical in 97%. Two or more of 
the queried symptoms were reported in 14% within the past 4 weeks of the baseline visit, 
most commonly itching (n=15), irritability (n=11), fatigue (n=7), depression/sadness (n=6), 
and nausea (n=6). None of the queried comorbid conditions were noted; although 6 children 
were currently taking medications, including bronchodilators (n=1), antihistamines (n=1), 
and ADHD medications (n=4).
Demographic characteristics of youth ≥10 years of age are found in Table 1.. Median ALT 
level was 41 (range: 13–2067) U/L. 69% were HBeAg positive, with high HBV DNA levels 
(≥108 IU/mL or above limits of quantification) in 47%. INR ranged from 0.8–4.1, albumin 
3.4–5.2 g/dL, and direct bilirubin 0.0–0.82 mg/dL. Median APRI was 0.33, with values 
above 1.0 in six participants (4.3%). Vertical transmission was suspected in 95%. Nearly 
one-third (29%) reported 2 or more of the queried symptoms within the past 4 weeks, most 
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commonly fatigue (n=44), irritability (n=37), itching (n=24), depression/sadness (n=20), 
poor appetite (n=20), nausea (n=16), pain over liver (n=13), and weight loss (n=10). Queried 
comorbid conditions were noted in 5 children: anemia (n=2), anemia and cytopenia (n=1), 
diabetes (n=1), and non-alcoholic fatty liver disease (n=1). Medication use was noted in 28 
(4 of whom used multiple medications): bronchodilators (n=9), antihistamines (n=7), 
antidepressants/anxiolytics/antipsychotics (n=5), ADHD medication (n=4), acne medication 
(n=4), estrogen/birth control pills (n=2), and analgesic/pain medications (n=1).
HRQoL among children with chronic HBV
Among 5–<10 year-olds, mean T-scores for the two summary scales (physical and 
psychosocial) were 54.1 (SD 6.3) for the PHS, and 52.8 (SD 8.2) for the PSS (not shown). 
Mean subscale scores for subscales related to physical HRQoL ranged from a low of 71.9 
(SD 13.9) for GH, to 97.8 (SD 9.7) for RP (Figure 1A). For subscales related to 
psychosocial HRQoL, mean scores ranged from 79.3 (SD 15.3) to 97.2 (SD 10.1) for the BE 
and REB subscales, respectively. Family-related components ranged from a mean of 74.2 
(SD 23.7) to 88.2 (SD 21.1) on the PE and PT subscales, respectively.
In children ≥10 years old, mean physical HRQoL subscale scores ranged from 71.8 (SD 
14.2) (GH) to 96.7 (SD 10.9) (RP), whereas mean psychosocial HRQoL subscale scores 
ranged from 77.8 (SD 14.5) for MH, to 94.1 (SD 16.2) for RB (Figure 1B). The FA subscale 
had a mean of 81.5 (SD 20.1).
Table 2a and b present mean (95% CI) PF 50 (a) and CF87 (b) subscale scores for the 
HBRN Pediatric Cohort, side-by-side with scores from other clinical pediatric populations. 
Scores from these populations cannot be compared statistically because of important 
differences in demographic characteristics between the groups. Instead, they provide an 
understanding of the range of scores in normative and chronically ill populations.
Comparison of HRQoL by Selected Characteristics
Summary T-Scores for 5–<10 year olds (PF50)—In 5–<10 year-olds, mean Physical 
and Psychosocial Summary T-scores were not associated with sex, adoption status, maternal 
education, symptom count, or APRI (p>0.05, Supplemental Digital Content, Table 3a, 
Participant characteristics and unadjusted associations with caregiver reported HRQoL 
(PF50) summary T-scores among children 5–<10 years of age in HBRN). Spearman 
correlation coefficients for ALT with the Physical and Psychosocial Summary T-scores were 
−0.08 (p>0.05) and −0.28 (p=0.01), respectively. That is, increasing ALT levels were 
associated with decreased psychosocial HRQoL.
Subscale Scores for 5–<10 year olds (PF50)—For males, the lowest median scores 
were observed for general health (72.5) and parent impact-emotional (66.7) subscales. For 
females, the lowest median scores were observed for general health (71.7) and mental health 
(80.0). For children living with biological parents, the general health subscales had the 
lowest median score (69.6), with all other components above 80.0. For adoptees, median 
scores were below 80.0 for both general health (72.5) and parent impact-emotional (75.0). 
Among children of mothers who did not have at least a bachelor’s degree, four subscales had 
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median scores below 80.0: general health (70.8), behavior (72.5), mental health (75.0), and 
parent impact-emotional (66.7). For children of mothers with a bachelor’s degree or higher, 
only the general health subscale median (72.5) was below 80.0. Very little variability was 
observed for the physical functioning, role functioning-physical, bodily pain, role 
functioning-emotional/behavioral and parent impact-time subscales: each had a median 
score of 100.0 across categories of sex, adoption status and maternal education 
(Supplemental Digital Content, 3b, Participant characteristics and unadjusted associations 
with caregiver reported HRQoL (PF-50) domains among children 5–<10 years of age in 
HBRN). In fact, ≥85% of participants obtained the maximum score of 100 for the physical 
functioning, role functioning-physical and role functioning-emotional/behavioral subscales, 
regardless of sex, adoptions status or maternal education.
Despite the association of lower Psychosocial T-score with increasing ALT, none of the 
PF50 subscale comparisons, including those by symptom count or ALT, were statistically 
significant.
Subscale Scores for 10–<18 year olds (CF87)—Among youth, median subscale 
scores ranged from 69.6 to 100.0 and 73.8 to 100.0 for males and females, respectively 
(Table 4). Across all subscales, comparisons by sex, ALT, and APRI were not statistically 
significant. Median scores ranged from 67.5 to 100.0 and 75.8 to 100.0 for non-adoptees and 
adoptees, respectively. Adoption status was statistically significantly associated with 
physical functioning (p<0.01): 15% of non-adoptees and 5% of adoptees scored <100.0. 
Adoption status was also associated with general health: lower median scores were observed 
among non-adoptees (p<0.001). Median scores ranged from 70.8 to 100.0 and 73.3 to 100 
for children of mothers with less than versus at least a bachelor’s degree. Maternal education 
was statistically significantly associated with role/functioning-physical (p=0.02) and role/
functioning-emotional scales (p=0.03). More youth of mothers with less than a bachelor’s 
degree (versus at least a bachelor’s degree) scored below 100.0 on the role/functioning-
physical (20% versus 3%) and -emotional subscales (33% versus 13%).
As compared to adoptees, non-adoptees were more likely to have mothers with a lower 
education level. This was true for both the 5–<10 year olds (23% of adoptees v. 45% of non-
adoptees had mothers with less than a bachelor’s degree, p = 0.051) but was most striking 
for youth (23% of adoptees v. 75% of non-adoptees had mothers with less than a bachelor’s 
degree, p = 0.01)
The number of reported symptoms (regardless of the specific symptom(s)) was significantly 
associated with 4 of 10 subscales: bodily pain, behavior, mental health, and self-esteem 
(p<0.01). For behavior, mental health and self-esteem subscales, median scores were lowest 
for those with 3+ symptoms, and highest for those with no symptoms. For the bodily pain 
subscale, median scores were 100.0 for each group other than those with 3+ symptoms 
(median 80.0). The proportion of youth scoring less than 100.0 on the bodily pain subscale 
was highest for those with the most symptoms (0 symptoms: 36%, 1 symptom: 38%, 2 
symptoms: 39%, and 3+symptoms: 75%).
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Discussion
This study examines HRQoL in the largest cohort of children with chronic HBV assembled 
in the US and Canada. Our cohort was generally asymptomatic with a low frequency of co-
morbid conditions and overall HRQoL similar to the normal range for healthy children. 
However, our study showed that clinical factors are associated with HRQoL in children with 
chronic HBV in several crucial ways. First, among young children, increased ALT levels 
were negatively associated with children’s parent-reported overall psychosocial functioning, 
an important association for clinicians to consider when caring for young children with HBV 
and their families. Our data cannot determine if this results from the direct effect of HBV 
disease or from the parent’s perception of diminished health as a result of knowing the 
child’s ALT levels. While liver biopsies were not available to stage disease in our cohort, 
APRI scores were in a normal range in most patients, suggesting the likely absence of 
significant hepatic fibrosis or inflammation in this cohort (18). Clinicians should know that 
caregivers of children with chronic hepatitis B and elevated ALT may be experiencing an 
emotional impact that they may not reveal in the clinical visit.
Second, older children reported more physical symptoms, and the number of these 
symptoms was associated with reports of worse HRQoL related to bodily pain, mental 
health, self-esteem, and behavior. Report of sadness and depression increased in the older 
age group and 5 of the children reported medication for these conditions. For clinicians, this 
means that the well-appearing child with few serologic markers of significant liver disease 
may still be experiencing impairment in facets of HRQoL. Adults with chronic HBV have a 
high risk of depression and anxiety (19, 20). In adolescents after liver transplantation 
(predominantly for biliary atresia, autoimmune hepatitis, and hepatitis (type unspecified)), 
low HRQoL was associated with poor adherence to the prescribed medication regimen (7). 
Awareness of diminished HRQoL in children with chronic HBV may allow intervention to 
provide disease-specific education and psychosocial support early in adolescence and young 
adulthood, to reduce later depression and anxiety, and insure that prescribed anti-viral 
treatments are as successful as possible. There may be benefit in directly addressing the 
child’s and caregiver’s fears, which are revealed in the study questionnaires, but rarely 
openly discussed in the clinical setting. Future studies should explore whether caregivers of 
children with chronic HBV would benefit from improved education about the disease and its 
likely course, parent support groups, or clear guidelines regarding any limitations (or lack of 
limitations) on their child’s future.
Also in youth, adoption status was associated with physical functioning and general health, 
which were worse for non-adoptees. Youth with mothers with less than a bachelor’s degree 
reported more limitations in schoolwork or activities with friends. A similar association of 
lower maternal education and HRQoL was noted in studies of children after liver 
transplantation (21, 22) and children with kidney disease (22). The majority of our cohort 
was born outside North America (97%,), children of either adoption or immigrant families 
(23). For both young children and youth, non-adoptees were more likely to have mothers 
with lower education level. These observations suggest that reduced HRQoL in these youth 
may not be directly related to HBV status, but that socioeconomic status, and, perhaps, 
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immigration status, may contribute as well. Providers caring for children with hepatitis B 
may want to consider the more global health concerns facing this population.
It is tempting to ascribe some reduction in HRQoL in children with chronic HBV to stigma 
or discrimination perceived by parent or child. Chinese adults with chronic HBV experience 
more difficulties in interpersonal relationships as a result of stigma—they believe they bring 
trouble to their families and are less desirable as spouses (24). They also report feeling 
stigma related to employment and physical relationships. Among Chinese adults living in 
Canada, stigma associated with chronic HBV infection is a reason for avoiding HBV 
screening (25). No similar studies have been performed in children.
Our data affirms the usefulness of HRQoL in children with liver disease as a measure of 
disease impact on the lives of parents and children. A similar study of HRQoL in 114 
treatment naive children with chronic hepatitis C virus demonstrated that, relative to 
normative data, caregivers were more likely to believe their child’s health was poor, reported 
higher concern about their child’s health status, and these perceptions limited family 
activities (26). In studies of children with non-alcoholic fatty liver disease (27) and 
autoimmune hepatitis (28), decreases in caregivers’ quality of life were found, although use 
of different HRQoL instruments makes direct comparison difficult. Information on HRQoL 
in children with chronic HBV is limited. Woo, et al., found no association of HRQoL and 
ALT in adults with hepatitis B, although they used a different HRQoL instrument from ours 
(29).
Our study has some limitations. Children were enrolled at tertiary medical centers; the 
population studied may not reflect the US and Canadian population of HBV-infected 
children. However, children are often referred to tertiary centers for evaluation and 
management even with asymptomatic HBV. The study was conducted in English because the 
HRQoL instrument was not translated into some of the languages most common among our 
non-English speakers. This may impact how well our study reflects the experiences of 
refugee children with HBV. Despite the large number of children enrolled in this study, our 
sample of young children with hepatitis B was small, and assessment of a larger cohort may 
be informative. Although population-normed scores are available for the PF50, there are 
important socio-demographic differences between the HBRN Pediatric Cohort and our 
comparison samples, particularly with respect to numbers of immigrant and adopted 
children, and ethnic and racial composition. Such differences make comparisons between 
the study and normative populations problematic, and were therefore not undertaken. 
Information from caregivers of youth was not available for this study, limiting direct 
comparison of caregivers’ impressions of HRQoL from childhood to adolescence. We were 
unable to evaluate fibrosis in our population; significant fibrosis is rare in children with 
HBV infection and is unlikely to be a determinant of HRQoL in this cohort.
Conclusion
Overall, HRQoL is preserved in children with chronic HBV infection. However, some socio-
demographic and HBV-related clinical factors were associated with impaired HRQoL in our 
pediatric cohort study sample at baseline, including elevated ALT in young children and 
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symptom-reporting, maternal education, and adoption status in youth. Measuring HRQoL 
may alert clinicians to children and families in need of psychological support and education 
to dispel health-related anxiety and reduce risk of non-adherence to therapy and subsequent 
behavioral and mood problems. This is crucial, as children with elevated ALT are more 
likely to need medical therapy for HBV, and early intervention may reduce poor adherence 
to therapy associated with reduced HRQoL. Future longitudinal studies in this cohort will 
track changes of HRQoL in children with the evolving clinical state of their chronic HBV.
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Refer to Web version on PubMed Central for supplementary material.
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What is known
Chronic hepatitis B (HBV) affects children of international adoption and refugees 
from countries where HBV is endemic
Adults with HBV have poor health-related quality of life (HRQoL) and are at risk 
for depression and other psychosocial disorders
What is new
In North American children with chronic HBV some socio-demographic and 
clinical factors were associated with impaired HRQoL, including elevated alanine-
amino-transferase in young children and symptom-reporting, maternal education, 
and adoption status in youth.
Measuring HRQoL may alert clinicians to children and families needing 
psychological support and education to dispel anxiety and reduce risk of non-
adherence to therapy and behavioral and mood problems.
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Figure 1. 
Mean scores (standard deviation) and 95% confidence interval of (A) subscale scores for 5–
<10 year olds (PF50) and (B) subscale scores for 10–<18 year olds (CF87). Solid lines 
demonstrate mean scores and dashed lines indicate 95% confidence intervals.
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Table 1
Demographic and Clinical Characteristics
Characteristics
All
N=244
Young children
5–<10 years
N=83
Youth
10–<18 years
N=161
Age, in yearsa N=244 N=83 N=161
11.89 (3.58) 7.68 (1.49) 14.05 (2.10)
Sexb N=244 N=83 N=161
 Male 95 (38.9%) 21 (25.3%) 74 (46.0%)
 Female 149 (61.1%) 62 (74.7%) 87 (54.0%)
Raceb N=242 N=82 N=160
 White 15 (6.2%) 3 (3.7%) 12 (7.5%)
 Black/African-American 30 (12.4%) 7 (8.5%) 23 (14.4%)
 Asian 188 (77.7%) 68 (82.9%) 120 (75.0%)
 Other 9 (3.7%) 4 (4.9%) 5 (3.1%)
Adoptedb N=244 N=83 N=161
131 (53.7%) 57 (68.7%) 74 (46.0%)
Maternal Educationb,e N=217 N=71 N=146
 Less than high school 26 (12.0%) 0 (0.0%) 26 (17.8%)
 High school or equivalent 25 (11.5%) 4 (5.6%) 21 (14.4%)
 Some college or equivalent 45 (20.7%) 17 (23.9%) 28 (19.2%)
 Bachelor’s degree or higher 121 (55.8%) 50 (70.4%) 71 (48.6%)
ALT (U/L)c N=240 N=82 N=158
40 (28, 54) 38 (26, 51) 40 (30, 54)
(12, 2067) (12, 365) (13, 2067)
HBeAgb N=228 N=76 N=152
 Negative 54 (23.7%) 7 (9.2%) 47 (30.9%)
 Positive 174 (76.3%) 69 (90.8%) 105 (69.1%)
HBV DNA (log10 IU/ml)d N=229 N=75 N=154
 Median (25th percentile, 75th percentile) 8.1 (5.3, 8.5) 8.2 (7.8, 8.7) 7.9 (4.0, 8.4)
 < 3 32 (14.0%) 6 (8.0%) 26 (16.9%)
 3 – < 6 31 (13.5%) 2 (2.7%) 29 (18.8%)
 6 – < 8 40 (17.5%) 13 (17.3%) 27 (17.5%)
 ≥8 126 (55.0%) 54 (72.0%) 72 (46.8%)
International Normalized Ratio (INR) c N=189 N=56 N=133
1.0 (1.0, 1.1) 1.0 (1.0, 1.0) 1.00 (1.0, 1.1)
(0.8, 4.1) (0.9, 1.2) (0.8, 4.1)
Albumin (g/dL)c N=218 N=74 N=144
4.4 (4.2, 4.6) 4.4 (4.2, 4.6) 4.3 (4.2, 4.6)
(1.1, 5.4) (1.1, 5.4) (3.4, 5.2)
Direct Bilirubin (mg/dL)c N=180 N=59 N=121
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Characteristics
All
N=244
Young children
5–<10 years
N=83
Youth
10–<18 years
N=161
0.08 (0.00, 0.10) 0.10 (0.0, 0.10) 0.00 (0.00, 0.12)
(0.00, 0.99) (0.00, 0.99) (0.00, 0.82)
APRI (AST-platelet-ratio index)c N=208 N=69 N=139
0.34 (0.26, 0.52) 0.37 (0.30, 0.52) 0.33 (0.25, 0.50)
(0.14, 12.31) (0.15, 2.31) (0.14, 12.31)
Total Symptom Count N=244 N=83 N=161
 0 135 (55.3%) 49 (59.0%) 86 (53.4%)
 1 51 (20.9%) 22 (26.5%) 29 (18.0%)
 2 25 (10.2%) 7 (8.4%) 18 (11.2%)
 3+ 33 (13.5%) 5 (6.0%) 28 (17.4%)
a
Mean (SD)
b
The first row gives the number of non-missing observations, followed by N (%) in each category.
c
The first row gives the number of non-missing observations. The second row gives median (25th percentile, 75th percentile), and the third row 
gives the (minimum, maximum).
d
The first row gives the number of non-missing observations. The second row gives median (25th percentile, 75th percentile), and the remaining 
rows give N (%) for each category.
e
For one child with two adoptive mothers, maternal education for the mother with ‘some college or equivalent’ was randomly selected for inclusion 
in this analysis; the other mother had a Master’s Degree. Maternal education level was set to missing for one child with a mother who was 
deceased.
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